$21.09
1.20% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
NL00150005Y4
Symbol
PHVS

Pharvaris NV Stock price

$21.09
-2.71 11.39% 1M
+3.39 19.15% 6M
+1.92 10.02% YTD
+5.36 34.08% 1Y
+4.07 23.91% 3Y
+1.09 5.45% 5Y
+1.09 5.45% 10Y
+1.09 5.45% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.25 1.20%
ISIN
NL00150005Y4
Symbol
PHVS
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.1b
Net debt
positive
Cash
$276.1m
Shares outstanding
54.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
91.9%
Return on Equity
-50.1%
ROCE
-70.6%
ROIC
-2,393.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-185.9m | $-203.7m
EBIT
$-186.3m | $-208.8m
Net Income
$-178.1m | $-197.7m
Free Cash Flow
$-157.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-53.3% | -20.6%
EBIT
-53.2% | -23.4%
Net Income
-43.5% | -26.8%
Free Cash Flow
-46.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.3
FCF per Share
$-2.9
Short interest
1.9%
Employees
83
Rev per Employee
$0.0
Show more

Is Pharvaris NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Pharvaris NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Pharvaris NV forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Pharvaris NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
44% 44%
-
- Research and Development Expense 130 130
58% 58%
-
-186 -186
53% 53%
-
- Depreciation and Amortization 0.36 0.36
20% 20%
-
EBIT (Operating Income) EBIT -186 -186
53% 53%
-
Net Profit -178 -178
44% 44%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pharvaris NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pharvaris NV Stock News

Neutral
GlobeNewsWire
about 5 hours ago
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of...
Positive
Seeking Alpha
20 days ago
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market...
Neutral
GlobeNewsWire
21 days ago
ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing...
More Pharvaris NV News

Company Profile

Pharvaris NV is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans G. C. P. Schikan and Anne Lesage on September 30, 2015 and is headquartered in Leiden, Netherlands.

Head office Netherlands
CEO Berndt Modig
Employees 83
Founded 2015
Website pharvaris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today